Clinical trial NCT03753893: Ocular Manifestations in Rheumatic Diseases
Official title: Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uveitis
Conjunctivitis
Keratoconjunctivitis Sicca
Xerophthalmia
Eye Hemorrhage
Optic Neuritis
Papilledema
Orbital Diseases
Retinal Vein Occlusion
Retinal Artery Occlusion
Macular Edema
Retinitis
Chorioretinitis
Iridocyclitis
Scleritis
Choroid Hemorrhage
Blindness
Amaurosis Fugax
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2018-11-27
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with ocular involvement in inflammatory rheumatic disease

Brief summary: This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

Detailed description: For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.

These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.

Eligibility criteria: Inclusion Criteria:

* Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in inflammatory rheumatic disease

Exclusion Criteria:

* review articles,
* case reports where all patients experienced the same ocular comorbidity
* if different comorbidities were not grouped independently
* if the study reported on fewer than 20 patients

Primary outcomes:
measure: Prevalence of ocular manifestations of inflammatory rheumatic diseases
timeFrame: data is collected once per year up to 2020
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
name: Janet Pope, MD
role: PRINCIPAL_INVESTIGATOR
References: